Start Date
January 31, 2022
Primary Completion Date
June 1, 2023
Study Completion Date
June 1, 2023
Blinatumomab
liposomal vincristine 2.25 mg/m2 weekly x 3 per cycle (weeks 3-5 in cycle 1 and 2-4 in subsequent cycles)
Novant Health Cancer Institute and Innovation Center, Winston-Salem
Duke University, Durham
Moffitt Cancer Center, Tampa
Collaborators (2)
Amgen
INDUSTRY
Acrotech Biopharma Inc.
INDUSTRY
Dorothy Sipkins, MD, PhD
OTHER